Investing.com -- 武田制药( Takeda Pharmaceutical Co Ltd ADR) (NYSE:TAK)股价上涨3.5%,此前该公司宣布其研究性嗜睡症治疗药物oveporexton的三期临床试验取得积极结果。 这家日本制药公司报告称,其潜在的首创口服促觉醒素受体2激动剂在两项针对1型嗜睡症的三期研究中达到了所有主要和次要终点。名为FirstLight和...
Source LinkInvesting.com -- 武田制药( Takeda Pharmaceutical Co Ltd ADR) (NYSE:TAK)股价上涨3.5%,此前该公司宣布其研究性嗜睡症治疗药物oveporexton的三期临床试验取得积极结果。 这家日本制药公司报告称,其潜在的首创口服促觉醒素受体2激动剂在两项针对1型嗜睡症的三期研究中达到了所有主要和次要终点。名为FirstLight和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.